From the European Society for Medical Oncology 2012 Congress: Additional safety, tolerability data for tivozanib versus sorafenib in metastatic RCC shows fewer adverse events
New data demonstrating the safety and tolerability profile of tivozanib versus sorafenib in the first-line setting for patients with metastatic renal cell carcinoma (RCC), was presented at ESMO's 2012 Congress.
People with ADHD had a 70% higher risk of death from any cause in a 19-study meta-analysis, with excess deaths from suicide, injury and natural causes.
Bronchiectasis affected 221.6 per 100,000 people in the U.S. over five years, which is higher than earlier national estimates, according to a study published in CHEST.
Adding Sunharbo (asundexian), a first-in-class factor XI inhibitor, to single or dual antiplatelet therapy reduces ischemic stroke risk without increasing the risk of major bleeding.
In this discussion, University College London colleagues Joshua Stott, Ph.D., professor of aging and clinical psychology and research assistant Lucy Corrigan, who led the work while at the University of Liverpool, talk about their recent meta-analysis linking ADHD to a higher risk of death from all causes, including suicide, injury and natural causes.
People with advanced Parkinson’s disease who also have a sleep disorder cost about $50,000 a year to treat, $13,000 more than similar patients without one, according to an AbbVie-funded claims analysis.